Real-world Efficacy and Safety of Low-Dose Abiraterone With Food and Standard-Dose Abiraterone in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Analysis.

Tu Anh DoPhuong Mai TranTrang Huyen VuHung Khac TranHuong Quynh NguyenLoi Dinh NguyenHong Thi NguyenChu Van Nguyen

Published in: Clinical genitourinary cancer (2024)

The LOW group and STD group showed effectiveness and safety in de novo high-risk mHSPC. The use of low-dose abiraterone in de novo mHSPC can significantly reduce treatment costs.

Keyphrases

low dose
prostate cancer
high dose
squamous cell carcinoma
small cell lung cancer
radical prostatectomy
risk assessment
combination therapy
human health